James Love's blog

Wikileaks on USTR negotiations with India Commerce Minister Anand Sharma

Among the cables recently published by Wilileaks is one written on November 24, 2009, detailing negotiations between USTR and Anand Sharma, the Cabinet Minister for Commerce and Industry of the Government of India. The complete cable is available here: http://wikileaks.org/cable/2009/11/09NEWDELHI2375.html

From Wikileaks, a US government cable on its involvement to shape Guatemala legislation on pharmaceutical IPR

August 28, 2011
From KEI staff review of Wikileaks cables (http://keionline.org/wikileaks)

Among the many new cables released by Wikileaks is this gem, a detailed account of the U.S. government pressure on the Guatemala legislature to shape legislation on pharmaceutical test data IPR.

http://wikileaks.org/cable/2005/03/05GUATEMALA659.html

C O N F I D E N T I A L SECTION 01 OF 05 GUATEMALA 000659

SIPDIS

E.O. 12958: DECL: 03/11/2010
TAGS: ETRD KIPR PGOV PREL GT

Notes from the Wikileaks cables (from the US Department of State)

Posted August 27, 2011

These are some tools for searching the US Department of State cables released by Wikileaks.

A Wikileaks page on the cables is available here: http://wlcentral.org/cablegate

KEI recommends this site for searching the cables by key words:

http://cablegatesearch.net/search.php

You might also want to try:

John LaMattian, former head of Pfizer R&D, says industry mergers have harmed R&D efforts

John L. LaMattina, the former President of Pfizer Global Research and Development, has just published an article in Nature that looks at the impact of drug company mergers and increased industry concentration on R&D. Among his conclusions: the "impact on the R&D of the organizations involved has been devastating."

http://www.nature.com/nrd/journal/v10/n8/full/nrd3514.html

COMMENT

NATURE REVIEWS | DRUG DISCOVERY VOLUME 10 | AUGUST 2011 | 559

The impact of mergers on pharmaceutical R&D

Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list

KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,

A full copy of the paper is available in PDF format here.

The following is from the introduction (sans footnotes, which are in the PDF version):

Introduction and Summary

KEI comment on the Medicines Patent Pool license with Gilead

KEI comment on the Medicines Patent Pool license with Gilead
July 12, 2011

FYI: James Love (Tuesday: +44.785.543.6510, james.love@keionline.org). Thiru Balasubramaniam (thiru@keionline.org) or Krista Cox (krista.cox@keionline.org, +1.202.332.2670).

SCCR debates way forward on new text for possible treaty for copyright exceptions for persons with disabilities

June 24: The current negotiating document on disabilities at the WIPO SCCR is SCCR/22/16. A new version Prov. 1 was passed out this morning.

U.S. employment and wages in 14 information sectors

I have another blog that deals with U.S. employment data from the information sector. This one provides May 2010 employment and wage data from fourteen 4- and 5-digit NAICS industry groups in the "Information Sector."

Notes on the data

KEI Statement in opposition to a WIPO Treaty for Broadcasting Organizations

KEI Statement on the Broadcast Treaty at WIPO SCCR 22
June 21, 2011

KEI opposes work at WIPO on a new treaty for broadcasting organizations.

To the extent that creative works are distributed through broadcasting networks, they are nearly always protected by copyright.

In the small cases where the broadcast involves material in the public domain, it would be a mistake to give the broadcaster an intellectual property right, merely for transmitting information.

BLS Estimates of Employment in the Sound Recording Industries

I was asked recently to look at some data on employment in the copyright industry. This addresses one set of data points, the BLS estimates of US employment in the Sound Recording Industries.

Occupational Employment Statistics

NAICS 2-Digit Industry Specific Estimates, May 2010

51 Information 2,708,760

NAICS 3-Digit Industry Specific Estimates, May 2010

511 Publishing Industries, except Internet, 758,090, 28.0%
512 Motion Picture and Sound Recording Industries, 371,450, 13.7%
515 Broadcasting (except internet), 292,010, 10.8%
517 Telecommunications, 909,780, 33.6%

Pictures from the WIPO SCCR negotiations on a treaty for persons who are blind or have other disabilities

These are pictures from the WIPO negotiations on a treaty for persons who are blind or have other disabilities.

Non paper distributed at SCCR 22 at 1pm on Friday, on disabilities

In a major breakthrough on the WIPO negotiations on copyright exceptions for persons with disabilities, at around 1pm today, a non-paper "resulting from informal discussions among Argentina, Brazil, Ecuador, the European Union and its Member States, Mexico, Paraguay and the United States of America" was distributed at the WIPO SCCR 22.

A copy of the document is available here:

http://keionline.org/sites/default/files/text_distributed_friday_1pm.doc

Report from SCCR 22 discussions of WIPO treaty for persons who are blind or have other disabilities

WBU_IMG_0931.JPG
Members of the WBU delegation at WIPO SCCR 22

June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations.

White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)

KEI Policy Brief 2011:1
June 11, 2011, Revised August 15, 2011

Pharmaceutical global R&D was 7.9 percent of sales in 2010

Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.


sales_rnd_2010_0.png
These are the data:

2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Indus...

2010 Global sales - $856 billion

Syndicate content